Quarterly report [Sections 13 or 15(d)]

Summary of Purchase Price Acquisition (Details)

v3.26.3
Summary of Purchase Price Acquisition (Details) - USD ($)
3 Months Ended
Jul. 28, 2026
Sep. 30, 2026
Asset Acquisition [Line Items]    
Fair value of Series A Preferred Stock issued to effect the Vidya Acquisition  
Common Stock [Member]    
Asset Acquisition [Line Items]    
Fair value of Series A Preferred Stock issued to effect the Vidya Acquisition  
Vidya Therapeutics, Inc. [Member]    
Asset Acquisition [Line Items]    
Total consideration [1] $ 175,000,000  
Cash acquired (102,000)  
Business Combination, Recognized Liability Assumed, Liability 467,000  
Net liabilities and IPR&D acquired 175,365,000  
Vidya Therapeutics, Inc. [Member] | Common Stock [Member]    
Asset Acquisition [Line Items]    
Fair value of the options to purchase Vidya common stock we assumed $ 1,280  
Series A Preferred Stock [Member]    
Asset Acquisition [Line Items]    
Multiplied by the fair value per share of our Series A Preferred Stock [2] $ 1.22119  
Series A Preferred Stock [Member] | Vidya Therapeutics, Inc. [Member]    
Asset Acquisition [Line Items]    
Number of shares of Series A Preferred Stock issued to the Vidya shareholders and option holders, as converted 142,254,972  
Fair value of Series A Preferred Stock issued to effect the Vidya Acquisition $ 173,720  
Total consideration $ 175,000,000  
[1] Represents the Vidya Acquisition research and development projects which were in process, but not yet completed, and which we may advance following the Vidya Acquisition, including the development of VT-7208. The fair value of IPR&D projects acquired in an asset acquisition with no alternative future use are charged to expense on the acquisition date. Substantially all of the fair value of the gross assets acquired was concentrated in the acquired IPR&D, a single identifiable asset, and the transaction therefore passed the screen test under ASC 805. Accordingly, the acquired set of assets did not meet the definition of a business. Additionally, the acquired assets did not include the outputs or meaningful processes necessary to be considered a business under ASC 805. The IPR&D was recorded at the fair value of the consideration given.
[2] The fair market valuation of the Series A Preferred Stock was determined based on the contractual conversion price per share, on an as-converted basis (1,000 shares of common stock for 1 share of Series A Preferred Stock).